Alchemy 21/12 files patent for AHK-Cu scalp formulation

Alchemy 21/12 has filed a U.S. provisional patent application for a patent-pending scalp technology built around AHK-Cu and controlled histidine ratios. The filing expands the company’s research focus on peptide signaling and copper-peptide chemistry in topical hair and scalp care.

Why it matters: - Alchemy 21/12 is trying to protect a formulation approach, not just a single ingredient. - The filing could strengthen the company’s position in scalp care products built around peptide signaling and copper-peptide chemistry. - The application may matter to consumers seeking non-drug, science-led scalp and hair formulations.

What happened: - Alchemy 21/12 announced on September 26, 2026 that its AHK-Cu hair and scalp technology is patent-pending. - The company filed U.S. Provisional Patent Application No. 64/163,219 with the U.S. Patent and Trademark Office. - The application is titled “Topical Scalp Compositions Comprising an Alanyl-Histidyl-Lysine Copper Complex and Free Histidine at Controlled Ligand Ratios.” - The patent filing covers topical compositions for the scalp and hair-bearing skin.

The details: - The claimed architecture centers on AHK-Cu, also known as Copper Tripeptide-3. - The filing also covers separately supplied free histidine at controlled ligand ratios. - The application includes defined formulation conditions for topical use. - The patent-pending technology grew out of work on Alchemy 21/12 AHK Peptide Hair + Scalp Serum. - The serum was built around AHK-Cu and a complementary peptide system. - The serum was developed as a non-drug approach to scalp care. - Alchemy 21/12 says the serum was designed to support the biological processes associated with healthy-looking hair and scalp function. - AHK-Cu is described as a naturally derived copper-binding tripeptide studied for its relationship to cellular signaling and processes relevant to hair and skin biology. - The company’s patent focus is the chemical environment around the copper-peptide complex, not only the presence of AHK-Cu. - The filing also emphasizes controlled use of free histidine within that architecture.

Between the lines: - Founder Jen Valenti is positioning the company around formulation design rather than ingredient marketing. - Valenti said the goal is to understand how chemistry can work with biology instead of overpowering it. - The filing suggests Alchemy 21/12 is betting that formulation context, stability and delivery matter as much as the active ingredient itself. - The company’s language points to a broader industry trend: cosmetic brands increasingly frame products around signaling, communication and molecular environment.

What’s next: - The provisional filing gives Alchemy 21/12 a first step toward broader patent protection. - The company says the filing is its first patent application. - Alchemy 21/12 is likely to keep building around peptide signaling, copper-peptide chemistry and biologically informed formulation design. - The company may use the patent-pending status to support future scalp-care product development.

The bottom line: - Alchemy 21/12 is turning a scalp serum concept into a protected formulation platform, with patent claims centered on how AHK-Cu, histidine and the surrounding chemistry work together.